文献速递肝病消化道肿瘤与早癌

移植肿瘤学时代原发性肝癌的肝移植

Liver transplantation for primary liver cancers in the era of transplant oncology.
PubMed 文献 · J Hepatol · 2026-01-01

肝移植仍是部分原发性肝脏恶性肿瘤患者最有效的根治性手术方式,其候选资格取决于基于预测总生存和移植获益的动态「合格窗口」,而非仅技术可行性。新辅助桥接、降期和转化治疗扩大了部分晚期患者的移植资格;移植后需平衡免疫抑制与肿瘤免疫监视,循环肿瘤DNA等新兴生物标志物有望优化候选选择和复发监测。

要点

  • 肝移植候选资格由预测总生存和移植获益的动态「合格窗口」决定,需反复评估肿瘤负荷、生物学和应答。
  • 新辅助桥接、降期和转化治疗已成为患者选择的核心,可扩大部分晚期患者的移植资格。
  • 移植后免疫抑制最小化需平衡移植物保护与肿瘤免疫监视,移植前免疫治疗后抗肿瘤免疫持久性尚不确定。

核心结论

  • 肝移植仍是部分原发性肝脏恶性肿瘤患者最有效的根治性手术方式,能同时处理肿瘤和基础肝病。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 移植候选资格由基于预测总生存和移植获益的动态「合格窗口」定义,需反复评估肿瘤负荷、生物学和应答。

关键数值与推荐

  • 移植应视为涵盖患者选择、新辅助治疗、移植物获取、手术和长期术后管理的多步骤过程。
  • 新辅助策略包括桥接、降期和转化治疗,通过系统与局部治疗组合扩大部分晚期患者的移植资格。
  • 移植后免疫抑制最小化至关重要,以平衡移植物保护与肿瘤免疫监视。
  • 循环肿瘤DNA、循环肿瘤细胞和microRNA等新兴生物标志物有望改善候选选择、检测微小残留病和早期识别复发。

临床怎么用

  • 临床应将肝移植视为多步骤过程,动态评估肿瘤负荷、生物学和治療应答以确定候选资格。
  • 合理运用桥接、降期和转化治疗扩大部分晚期患者的移植资格。
  • 移植后实施免疫抑制最小化,并关注新兴生物标志物用于复发监测。

局限性

  • 移植前免疫治疗后抗肿瘤免疫的持久性尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver transplantation (LT) remains the most effective curative-intent surgical approach for selected patients with primary hepatic malignancies, owing to its ability to completely replace the diseased liver and address both the tumour and the underlying liver disease. Rather than being determined solely by technical feasibility, transplant candidacy is defined by a dynamic "window of eligibility" based on predicted overall survival and transplant benefit, with repeated assessment of tumour burden, biology, and response to therapy. LT should therefore be viewed as a complex, multi-step process encompassing patient selection, neoadjuvant treatment, graft procurement, surgery, and long-term postoperative management. Neoadjuvant strategies, including bridging, downstaging, and conversion therapies, have become central to patient selection and have expanded transplant eligibility for selected patients with advanced disease through combinations of systemic and locoregional treatments. Following transplantation, minimisation of immunosuppression is essential to balance graft preservation against tumour immune surveillance, although the persistence of antitumour immunity after pre-transplant immunotherapy remains uncertain. Emerging biomarkers, including circulating tumour DNA, circulating tumour cells, and microRNAs, have the potential to improve candidate selection, detect minimal residual disease, and enable earlier, biology-driven identification of recurrence, thereby supporting a more personalised approach to LT in primary liver cancers.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Mazzaferro V, Pinter M, Pillai A, et al. Liver transplantation for primary liver cancers in the era of transplant oncology. J Hepatol. 2026. PMID: 42744523. doi:10.1016/j.jhep.2026.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。